StoneX Group’s Revelation Biosciences REVB Stock Holding History

StoneX Group’s Portfolio REVB Stock Details REVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-851	Closed	-$7.66K	–	1002
2025 Q2	$7.66K	Buy	+851	New	+$22.3K	﹤0.01%	843
2025 Q1	–	Sell	-74	Closed	-$6.52K	–	954
2024 Q4	$6.52K	Buy	+74	New	+$9.86K	﹤0.01%	818

Other funds holding REVB

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

StoneX Group's REVB Position: Q3 2025 in Review

StoneX Group sold out of Revelation Biosciences (REVB) in Q3 2025, closing a stake of 851 shares — an estimated $7.66K sold.

StoneX Group first reported a position in REVB in Q4 2024 and held it in 2 quarters. The position peaked at $7.66K in Q2 2025. 8 funds tracked by Wall St. Rank hold REVB as of Q3 2025.

StoneX Group reported no remaining Revelation Biosciences position as of Q3 2025 after selling out during the quarter.
StoneX Group sold 851 Revelation Biosciences shares in Q3 2025, an estimated $7.66K.
StoneX Group first reported a position in Revelation Biosciences in Q4 2024 and held it in 2 quarters.
StoneX Group's Revelation Biosciences position peaked at $7.66K in Q2 2025.
8 funds tracked by Wall St. Rank held Revelation Biosciences as of Q3 2025.

Based on StoneX Group's 13F filing for Q3 2025, filed 14 Nov 2025.